News - Cardio-vascular, The Medicines Company

Filter

Popular Filters

FDA advisory committee votes against approval of antiplatelet therapy cangrelor

FDA advisory committee votes against approval of antiplatelet therapy cangrelor

13-02-2014

The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday…

cangrelorCardio-vascularPharmaceuticalRegulationThe Medicines CompanyUSA

Swedish registry questions superiority of bivalirudin over heparin in patients undergoing PCI for NSTE-ACS

22-05-2013

Results from a large observational study reported at EuroPCR 2013 (the official annual meeting of the…

AngiomaxbivalirudinCardio-vascularheparinPharmaceuticalResearchThe Medicines Company

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol

05-02-2013

USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

The Medicines Company expands into Russian pharmaceutical market

14-06-2012

US drugmaker The Medicines Company (Nasdaq: MDCO) is expanding into Russia, through the start of sales…

AngioxCardio-vascularEuropeMarkets & MarketingPharmaceuticalThe Medicines Company

AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars

26-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its…

AstraZenecaCardio-vascularFinancialLicensingManagementPharmaceuticalThe Medicines Company

The Medicines Co settles with APP over Angiomax

24-01-2012

The Medicines Company (Nasdaq: MDCO) says that it has settled the law suits filed by company in the US…

AngiomaxAPP PharmaceuticalsCardio-vascularFresenius KabiGenericsLegalNorth AmericaPatentsPharmaceuticalThe Medicines Company

Back to top